{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United States Medical Distribution news", "home_page_url": "https://sharemaestro.com/newsreel/us/healthcare/medical-distribution/", "feed_url": "https://sharemaestro.com/newsreel/us/healthcare/medical-distribution/feed.json", "description": "Latest Medical Distribution company headlines from United States, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:923840a1ded655d3548b540996762ea0199fa7aa6bd318dc8612ca9498d97dfe", "url": "https://finance.yahoo.com/video/cardinal-health-ceo-details-m-182948264.html", "external_url": "https://finance.yahoo.com/video/cardinal-health-ceo-details-m-182948264.html", "title": "Cardinal Health CEO details M&A strategy and growth", "content_text": "Jason Hollar, Cardinal Health (CAH) CEO joins Yahoo Finance Executive Editor Brian Sozzi to detail how M&A strategy, specialty pharma growth, and drug volume dynamics are driving profits. Video Transcript 00:00 Speaker A Where do you want to take this business with acquisitions? 00:02 Speaker B Yeah, so we've invested heavily to to acquire the platforms that we wanted to use to accelerate our strategy. So specialty is is by far the fastest growing part of the pharma market. It's an area where we still see a lot of opportunity, uh not just in terms of the organic growth there, but we accelerate", "date_published": "2026-08-14T18:29:48+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:93a4cf39d41a8117416ec597abba7e1d003a024cc99d4cf3bad9664ed228a918", "url": "https://finance.yahoo.com/healthcare/articles/cencora-cor-leveraging-healthcare-growth-120601766.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cencora-cor-leveraging-healthcare-growth-120601766.html", "title": "Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity", "content_text": "Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the \"Insiders Fund\". A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500's -0.95%, 15.2%, and 9.98% returns, respectively, over the same period. The fund underperformed while the S&P 500 and Nasdaq-100 posted their best quarter in six years. A significant factor in this decline is a ~30% concentration in Alphabet stock, which shifted from a cash-generating asset to a capital-intensive postur", "date_published": "2026-08-14T12:06:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:69d5880d25e816ffd40ccc3ce046a9566d12d3a8655d2c8410a4a82d537dd6eb", "url": "https://finance.yahoo.com/markets/stocks/articles/5-insightful-analyst-questions-cencora-070100185.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/5-insightful-analyst-questions-cencora-070100185.html", "title": "5 Insightful Analyst Questions From Cencora\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Cencora's Q2 Earnings Call Cencora's second quarter was marked by performance that met Wall Street's expectations on revenue and exceeded consensus on non-GAAP profitability, driving a positive market response. Management credited execution in specialty pharmaceuticals, especially through its Management Services Organizations (MSOs) like OneOncology and RCA, as a core driver of growth, while digital transformation initiatives improved operational efficiency. CEO Robert Mauch highlighted the company's unique positioning in specialty care, stating, \"Our specia", "date_published": "2026-08-14T07:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:db5676ebd87fe520622cb2fb5b20c7b497e67d3fe6f5263127db3fe579419776", "url": "https://kalkinemedia.com/uk/news/announcements/hsbc-bank-plc-reports-no-stabilisation-in-national-grid-north-america-incs-eur-13-billion-dual-tranche-euro-bond-issue", "external_url": "https://kalkinemedia.com/uk/news/announcements/hsbc-bank-plc-reports-no-stabilisation-in-national-grid-north-america-incs-eur-13-billion-dual-tranche-euro-bond-issue", "title": "HSBC Bank Plc Reports No Stabilisation in National Grid North America Inc's EUR 1.3 Billion Dual-Tranche Euro Bond Issue", "content_text": "HSBC Bank plc has confirmed that no stabilization activities were conducted for National Grid North America Inc's EUR 1.3 billion dual-tranche euro-denominated bond issue. The bond offering includes EUR 700 million at 3.643% notes due April 2031 and EUR 600 million at 4.268% notes due April 2037, both priced at 99.999. This regulatory disclosure indicates that the bonds traded without price-support intervention from HSBC, which acted as the Stabilising Manager.", "date_published": "2026-08-14T06:40:08+00:00", "authors": [{"name": "Kalkine Media"}], "tags": ["Regulatory and legal", "HSIC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "HSIC", "name": "Henry Schein Inc", "sentiment_url": "https://sharemaestro.com/sentiment/7e68109e-ccb7-48b4-baa6-5f2259f53a97/"}]}}, {"id": "source:5a155b5cb8616cd51c5b3a9eca0282b90a1ef8317f46d88a673dfcb18e795aaa", "url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-stock-hits-record-221000916.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-stock-hits-record-221000916.html", "title": "Cardinal Health Stock Hits a Record High After Earnings: Is CAH Still a Buy?", "content_text": "Cardinal Health CAH gave investors plenty to like in its fiscal fourth-quarter report this week, sending shares to a record high of $258 as Wall Street digests another earnings beat and an encouraging fiscal 2027 outlook. The Dividend Aristocrat's quarterly sales came in below expectations, but that was overshadowed by stronger-than-anticipated profitability, double-digit projected earnings growth, and a sizable increase to its share-repurchase authorization. With Cardinal Health also expanding several higher-growth businesses, the post-earnings setup remains compelling even after an impressiv", "date_published": "2026-08-13T22:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:bb1df3cc8018d34d8ccf3ff646d7185d74853a0b2d8fef4369f52d4c769cb6c0", "url": "https://www.benzinga.com/news/26/08/61195735/if-you-invested-1000-cencora-stock-10-years-ago-you-would-have-much-today", "external_url": "https://www.benzinga.com/news/26/08/61195735/if-you-invested-1000-cencora-stock-10-years-ago-you-would-have-much-today", "title": "If You Invested $1000 In Cencora Stock 10 Years Ago, You Would Have This Much Today", "content_text": "Cencora (NYSE: COR) has significantly outperformed the market over the last decade, with an average annual return of 19.83%. An initial investment of $1000 in COR stock ten years ago would now be worth $6,070.40, highlighting the power of compounded returns. The company currently holds a market capitalization of $59.16 billion.", "date_published": "2026-08-13T20:45:29+00:00", "authors": [{"name": "Benzinga"}], "tags": ["Market update", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:82d6e0858507ed9561e47eb148a1898564770fbb372596ac5475ad9e58bcb34f", "url": "https://www.stocktitan.net/sec-filings/CAH/schedule-13g-cardinal-health-inc-passive-investment-disclosure-5-008ff110b599.html", "external_url": "https://www.stocktitan.net/sec-filings/CAH/schedule-13g-cardinal-health-inc-passive-investment-disclosure-5-008ff110b599.html", "title": "Wellington Group (CAH) discloses 6.34% beneficial stake in Cardinal Health", "content_text": "Wellington Management Group LLP and its affiliated entities have disclosed a 6.34% beneficial ownership stake in Cardinal Health, Inc. (CAH) as of June 30, 2026. This ownership, totaling 14,860,271 shares, is primarily held on behalf of various advisory clients, explaining the shared voting and dispositive power. The filing emphasizes that no single client holds more than 5% of the class.", "date_published": "2026-08-13T20:06:22+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:8d8f90e05921e6c4ff146a2b3b46f0bc6533fcb03d9ed64573f38211db414ba1", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQdjBIYW1nYWZqcEdWcmMzVWJ6STNDMUJ6QTVGUFd0Vlg2bzgwMWV1X2Y3SUFkeUxlVEdlS094ZEZweGdIbnpMZml2Qk1LQ2xQWGlOYmd2MGI5YWhEbzVoY0doemNPQmxtZGsyd2tFaVBjLVRpemR5Qmk5dmMyS0lETVJ3NDZjTWJUTWZRUnRSODhlTzZ2bFNXRVpUd1plcG5nSVZPdnlyNXRMZG8?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQdjBIYW1nYWZqcEdWcmMzVWJ6STNDMUJ6QTVGUFd0Vlg2bzgwMWV1X2Y3SUFkeUxlVEdlS094ZEZweGdIbnpMZml2Qk1LQ2xQWGlOYmd2MGI5YWhEbzVoY0doemNPQmxtZGsyd2tFaVBjLVRpemR5Qmk5dmMyS0lETVJ3NDZjTWJUTWZRUnRSODhlTzZ2bFNXRVpUd1plcG5nSVZPdnlyNXRMZG8?oc=5", "title": "Cardinal Health Stock Loses $912 Million as Recall Searches Test a $63.7 Billion Quarter", "content_text": "Cardinal Health Stock Loses $912 Million as Recall Searches Test a $63.7 Billion Quarter", "date_published": "2026-08-13T19:59:00+00:00", "authors": [{"name": "TechStock\u00b2"}], "tags": ["Regulatory and legal", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:06fd16a4ce19200e9a5721c3b1ade3fefb957d195d36ab5462125137c203bc3a", "url": "https://www.hmenews.com/article/cardinal-health-sees-more-runway-in-fragmented-at-home-medical-supplies-market", "external_url": "https://www.hmenews.com/article/cardinal-health-sees-more-runway-in-fragmented-at-home-medical-supplies-market", "title": "Cardinal Health sees more runway in fragmented at-home medical supplies market", "content_text": "Cardinal Health's acquisitions of Strive Medical and AdaptHealth's diabetes business are projected to add two percentage points of growth to its Other segment in fiscal year 2027, strengthening its position in the at-home medical supplies and diabetes markets. CEO Jason Hollar highlighted the fragmented nature of the market as an opportunity for scaling and improving offerings. These strategic moves align with Cardinal Health's multi-year investment plan to expand in high-growth areas and leverage efficiencies.", "date_published": "2026-08-13T14:07:21+00:00", "authors": [{"name": "HME News"}], "tags": ["Deals and strategy", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:a57ab9ff6bf4a20b8173e3a2b86a423a6a332c7531d73d20ba9a5faee830400f", "url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "external_url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "title": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs", "content_text": "Revvity, Inc. RVTY recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex initially will be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026. Per management, the SuperFlex system represents a significan", "date_published": "2026-08-13T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:e22c8bff35da0fdeaab3ea09e91096c28ce3754dd67aef6346460ac471d645d6", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPWVJsLU50eHJNc0phTl9XZ2twUkctZVdNcEE4WVZqVTFyMUtRTzh2RlRpOXV0M2hESEVCX19SNk9zUTZrbk9ORVhia3ktQmF0MGVVZGhSZWZRbVpCQ2RvRVdaMUE4M1JlOHRBdm1KNklkUXozbHpvZHNOTU8wUjhXNDZvN3EyMUJfaUJVRDFSc3NNSTM4a3piNmlzakdZc3JMdFdnd0FnNVY5SXRZMl9FNFhJUnJweUtqSXc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPWVJsLU50eHJNc0phTl9XZ2twUkctZVdNcEE4WVZqVTFyMUtRTzh2RlRpOXV0M2hESEVCX19SNk9zUTZrbk9ORVhia3ktQmF0MGVVZGhSZWZRbVpCQ2RvRVdaMUE4M1JlOHRBdm1KNklkUXozbHpvZHNOTU8wUjhXNDZvN3EyMUJfaUJVRDFSc3NNSTM4a3piNmlzakdZc3JMdFdnd0FnNVY5SXRZMl9FNFhJUnJweUtqSXc?oc=5", "title": "Cardinal Health: Q4 Presents Positive Signal For The Company's Long-Term Growth (NYSE:CAH)", "content_text": "Cardinal Health: Q4 Presents Positive Signal For The Company's Long-Term Growth (NYSE:CAH)", "date_published": "2026-08-13T13:53:06+00:00", "authors": [{"name": "Seeking Alpha"}], "tags": ["Market update", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:588872d83d7698f2744870cd208a5f25049ac8d798e7bc90774e01eb646baf80", "url": "https://finance.yahoo.com/healthcare/articles/bwx-technologies-nuclear-medicine-expansion-132900353.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bwx-technologies-nuclear-medicine-expansion-132900353.html", "title": "Can BWX Technologies' Nuclear Medicine Expansion Boost Growth?", "content_text": "BWX Technologies, Inc. BWXT is broadening its commercial nuclear portfolio through expanded capabilities in nuclear medicine and medical radioisotopes. The company's acquisition of Kinectrics in May 2025 added capabilities in the production and supply of isotopes for the radiopharmaceutical industry, enabling BWXT to expand its presence across both nuclear power and nuclear medicine markets. BWX Technologies' commercial operations segment already provides products for diagnostic imaging and radiotherapeutic treatments, including medical radioisotopes, radiopharmaceuticals and medical devices. ", "date_published": "2026-08-13T13:29:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:e429ec4981b80c70c477c6884ac66dfad9b345763e9d97d93c4f4c3832bb2f8c", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-add-cooper-companies-125100087.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-add-cooper-companies-125100087.html", "title": "Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now", "content_text": "The Cooper Companies, Inc.'s COO growth is fueled by CooperVision's premium lens migration and MiSight's myopia-management leadership, supported by CooperSurgical's women's health and fertility portfolio. However, channel volatility, private-label transition risks, Asia-Pacific softness and tariff/FX pressures weigh on near-term performance. Long-term opportunities remain strong, but execution and regional challenges could affect margin resilience and growth trajectory. Shares of this Zacks Rank #2 (Buy) company have lost 6.3% so far this year against the industry's 7.4% gain and the S&P 500 I", "date_published": "2026-08-13T12:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CAH", "HSIC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}, {"symbol": "HSIC", "name": "Henry Schein Inc", "sentiment_url": "https://sharemaestro.com/sentiment/7e68109e-ccb7-48b4-baa6-5f2259f53a97/"}]}}, {"id": "source:e3c829b64acbac4512888c9f3e021923769fe63b8467d6a5ba03cdfb8a5c5668", "url": "https://www.marketscreener.com/news/jpmorgan-adjusts-cardinal-health-price-target-to-260-from-215-maintains-neutral-rating-ce7859d9df8ef120", "external_url": "https://www.marketscreener.com/news/jpmorgan-adjusts-cardinal-health-price-target-to-260-from-215-maintains-neutral-rating-ce7859d9df8ef120", "title": "JPMorgan Adjusts Cardinal Health Price Target to $260 From $215, Maintains Neutral Rating", "content_text": "JPMorgan has raised its price target for Cardinal Health (CAH) to $260 from $215, while maintaining a Neutral rating on the stock. This adjustment comes amidst several other analyst updates for Cardinal Health, with firms like Evercore ISI, TD Cowen, and Deutsche Bank also modifying their price targets and ratings around the same time. The company specializes in the distribution of pharmaceutical and medical products.", "date_published": "2026-08-13T12:37:23+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Analyst action", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:0fa544de371d9278b22871153335a0b8e6ea3269e5217b7acecaa6738ea3b544", "url": "https://www.marketscreener.com/news/evercore-isi-adjusts-cardinal-health-pt-to-270-from-265-maintains-outperform-rating-ce7859d9df8ef12d", "external_url": "https://www.marketscreener.com/news/evercore-isi-adjusts-cardinal-health-pt-to-270-from-265-maintains-outperform-rating-ce7859d9df8ef12d", "title": "Evercore ISI Adjusts Cardinal Health PT to $270 From $265, Maintains Outperform Rating", "content_text": "Evercore ISI has raised its price target for Cardinal Health (CAH) to $270 from $265, while reiterating an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm on the pharmaceutical distributor. The news highlights recent analyst activity around Cardinal Health, with several other firms also updating their price targets and ratings.", "date_published": "2026-08-13T12:07:25+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Analyst action", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:b8f78158a683391186b789bc0570587fce46aa5d5f7c65cb46b10531b1af1c31", "url": "https://www.marketscreener.com/news/deutsche-bank-adjusts-cardinal-health-price-target-to-261-from-223-maintains-hold-rating-ce7859d9df89f52c", "external_url": "https://www.marketscreener.com/news/deutsche-bank-adjusts-cardinal-health-price-target-to-261-from-223-maintains-hold-rating-ce7859d9df89f52c", "title": "Deutsche Bank Adjusts Cardinal Health Price Target to $261 From $223, Maintains Hold Rating", "content_text": "Deutsche Bank has updated its price target for Cardinal Health (CAH), increasing it to $261 from the previous $223, while keeping a \"Hold\" rating on the stock. This adjustment reflects new analyst valuations for the pharmaceutical distributor. The article also lists other recent analyst adjustments for Cardinal Health, with several firms raising their price targets and maintaining positive ratings.", "date_published": "2026-08-13T11:38:21+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Analyst action", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:1a3eb0b098a0368ddaeec7543c637648ddd9468884f27ddfe2c3956a2278cd19", "url": "https://www.morningstar.com/company-reports/1494758-cencora-walgreens-volume-disruption-raises-new-concern-but-we-make-no-changes-for-now?listing=0P000000ER", "external_url": "https://www.morningstar.com/company-reports/1494758-cencora-walgreens-volume-disruption-raises-new-concern-but-we-make-no-changes-for-now?listing=0P000000ER", "title": "Cencora: Walgreens Volume Disruption Raises New Concern, but We Make No Changes for Now", "content_text": "Cencora disclosed that a portion of the volume it serviced for Walgreens began moving elsewhere starting July 1, causing a 4% drop in shares. Despite this new concern, the company reaffirmed its full-year EPS guidance of $17.75-$17.95, and Morningstar analysts are not yet making changes to their ratings. The article notes this development while referring to previous positive reports on Cencora's growth rebound and strong specialty assets.", "date_published": "2026-08-13T11:37:30+00:00", "authors": [{"name": "Morningstar"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:48bb229b6bc0843d79ea5b3159b285fefeb5db9324756314c88101e30bfabf1c", "url": "https://www.marketbeat.com/instant-alerts/filing-insight-wealth-strategies-llc-trims-holdings-in-mckesson-corporation-mck-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/filing-insight-wealth-strategies-llc-trims-holdings-in-mckesson-corporation-mck-2026-08-13", "title": "Insight Wealth Strategies LLC Trims Holdings in McKesson Corporation $MCK", "content_text": "Insight Wealth Strategies LLC significantly reduced its stake in McKesson Corporation by 93.5% in the second quarter. This move comes as McKesson reported strong quarterly earnings, beating expectations with EPS of $9.93 and revenue of $105.38 billion, and raised its quarterly dividend to $0.94 per share. Despite the fund's selling, analysts largely maintain a \"Moderate Buy\" rating for MCK.", "date_published": "2026-08-13T09:35:44+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "MCK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/f408c6b7-f74b-4900-8d8c-02e6020cfb3f/"}]}}, {"id": "source:3a388e494f79e0e3d0cddb545f7d140c86ccb65e69ffa3d6ea2be4a007931c6b", "url": "https://www.theglobeandmail.com/investing/markets/stocks/INO-Q/pressreleases/3817961/inovio-ino-q2-2026-earnings-call-transcript", "external_url": "https://www.theglobeandmail.com/investing/markets/stocks/INO-Q/pressreleases/3817961/inovio-ino-q2-2026-earnings-call-transcript", "title": "Inovio (INO) Q2 2026 Earnings Call Transcript", "content_text": "Inovio (INO) discussed its Q2 2026 financial results and provided an update on its lead candidate, INO-3107, which has a PDUFA date of October 30, 2026. The company highlighted progress in regulatory reviews, commercial launch preparations, and positive Phase III results for VGX-3100 from its partner ApolloBio. Inovio also announced the expansion of its DPROT technology platform to include new rare disease targets, Fabry disease and hypophosphatasia.", "date_published": "2026-08-13T01:13:18+00:00", "authors": [{"name": "The Globe and Mail"}], "tags": ["Earnings", "HSIC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "HSIC", "name": "Henry Schein Inc", "sentiment_url": "https://sharemaestro.com/sentiment/7e68109e-ccb7-48b4-baa6-5f2259f53a97/"}]}}, {"id": "source:9c4b3f3aaf2b072379c9f5a05d7501e40529776589bff40c1821831a1aa0b8b5", "url": "https://www.marketwatch.com/data-news/cardinal-health-inc-stock-underperforms-wednesday-when-compared-to-competitors-c4471b1e-b525b41ffa5a?mod=mw_quote_news", "external_url": "https://www.marketwatch.com/data-news/cardinal-health-inc-stock-underperforms-wednesday-when-compared-to-competitors-c4471b1e-b525b41ffa5a?mod=mw_quote_news", "title": "Cardinal Health Inc. stock underperforms Wednesday when compared to competitors", "content_text": "Cardinal Health Inc. (CAH) stock declined by 2.54% on Wednesday, closing at $234.16. This underperformance occurred on a mixed trading day where the S&P 500 Index rose, and the Dow Jones Industrial Average slightly fell. The stock's drop ended a two-day winning streak.", "date_published": "2026-08-12T21:07:19+00:00", "authors": [{"name": "MarketWatch"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:7c83831e02074ec48296dcaab8ef5c45192158998d0a50575cee5fb07cd9b27c", "url": "https://www.marketwatch.com/data-news/mckesson-corp-stock-underperforms-wednesday-when-compared-to-competitors-302279ff-393fc69b0fa4", "external_url": "https://www.marketwatch.com/data-news/mckesson-corp-stock-underperforms-wednesday-when-compared-to-competitors-302279ff-393fc69b0fa4", "title": "McKesson Corp. stock underperforms Wednesday when compared to competitors", "content_text": "McKesson Corp. (MCK) shares fell by 2.55% on Wednesday, closing at $878.73. This underperformance occurred on a mixed trading day where the S&P 500 Index rose by 0.26% and the Dow Jones Industrial Average declined by 0.04%. The stock's drop ended a two-day winning streak.", "date_published": "2026-08-12T20:38:29+00:00", "authors": [{"name": "MarketWatch"}], "tags": ["Market update", "MCK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/f408c6b7-f74b-4900-8d8c-02e6020cfb3f/"}]}}, {"id": "source:a33678741bda28d3ecd180539c89719da3680f9d58e4dd8344347adc538a8e6e", "url": "https://www.marketwatch.com/data-news/cencora-inc-stock-underperforms-wednesday-when-compared-to-competitors-9b8b9a1b-092abb7b4bef", "external_url": "https://www.marketwatch.com/data-news/cencora-inc-stock-underperforms-wednesday-when-compared-to-competitors-9b8b9a1b-092abb7b4bef", "title": "Cencora Inc. stock underperforms Wednesday when compared to competitors", "content_text": "Cencora Inc. (COR) stock fell by 5.90% to $314.17 on Wednesday, underperforming the broader market. This drop occurred despite the S&P 500 Index seeing a slight gain, while the Dow Jones Industrial Average experienced a marginal decline. The stock's fall ended a two-day winning streak for Cencora.", "date_published": "2026-08-12T20:37:31+00:00", "authors": [{"name": "MarketWatch"}], "tags": ["Market update", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:4e6850ec9570a22fce9c01fe2e70bc3fe67a2c0c5b20af04a235df1c728eaeef", "url": "https://www.tradingkey.com/news/market-movers/262100370-market-movers-cor-20260812", "external_url": "https://www.tradingkey.com/news/market-movers/262100370-market-movers-cor-20260812", "title": "Cencora Inc Stock (COR) Closed Down by 5.92% on Aug 12: Key Drivers Unveiled", "content_text": "Cencora Inc (COR) stock closed down by 5.92% on August 12, primarily due to the confirmed transition of non-prime Walgreens pharmaceutical volume to competitors. Despite management reiterating full-year earnings per share guidance, investors focused on potential revenue risks and customer retention challenges in the competitive pharmaceutical distribution market. The company also faces headwinds from subdued revenue guidance, rising interest expenses, and asset impairments, overshadowing its industry-leading annual revenue of $321.33 billion.", "date_published": "2026-08-12T20:15:31+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:12988b2e263857dae1bc2b49513303f7c6e7e2cc704e0a023e0442e1d522ea65", "url": "https://finance.yahoo.com/markets/stocks/articles/us-equity-markets-end-mixed-201441316.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/us-equity-markets-end-mixed-201441316.html", "title": "US Equity Markets End Mixed Amid Tech Stock Gains, Lower Inflation Data", "content_text": "US equity indexes ended mixed Wednesday amid stock gains by some major technology stocks and a four-month low inflation rate report.* The consumer price index rose 3.4% in July from a year earlier, decelerating from 3.5% in June, according to data from the Bureau of Labor Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T20:14:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:43ed1a08e1f22883425ac676f0f7fa7866bfef1a4b23b9387abc220c4dd70e74", "url": "https://scanx.trade/stock-market-news/companies/cencora-reaffirms-17-75-17-95-fy26-eps-guidance-walgreens-shift/48108196", "external_url": "https://scanx.trade/stock-market-news/companies/cencora-reaffirms-17-75-17-95-fy26-eps-guidance-walgreens-shift/48108196", "title": "Cencora reaffirms $17.75-$17.95 FY26 EPS guidance amid Walgreens shift", "content_text": "Cencora confirmed that some Walgreens volume will shift outside its operations starting July 1, 2026, but its primary vendor agreement with Walgreens remains unaffected. The company reiterated its fiscal year 2026 adjusted diluted EPS guidance of $17.75-$17.95, stating that this change was already factored into previous Q4 expectations. This decision indicates the stability of its financial outlook despite the operational adjustment.", "date_published": "2026-08-12T20:07:26+00:00", "authors": [{"name": "scanx.trade"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:5fcdf767edc608cff7fa5cd79c787c8ad280036dafb0cd1562c8c5a696de8af4", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "title": "Sector Update: Healthcare Stocks Advance Late Afternoon", "content_text": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-12T19:58:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:4480e844406c41576cd63c312530df301266d605de5aea17984fea460eaa2e65", "url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-cah-stock-looks-191207319.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-cah-stock-looks-191207319.html", "title": "Cardinal Health (CAH) Stock Looks About Right On Earnings But Stretched On Broader Checks", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. After a very strong multi year run, Cardinal Health stock is now being judged by a low overall value score and fresh questions about risk controls, so investors are weighing whether the current price still fairly reflects its fundamentals. Cardinal Health has delivered about 409.2% over the past 5 years, which sets expectations high for what comes next. The recent levothyroxine tablet recalls and the appointment of a new Chief Accounting Officer may affect how the market pric", "date_published": "2026-08-12T19:12:07+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:2d500db5f34867de65f8d6450295a373fd2a5d67a038efdf21f3688bc9ce88de", "url": "https://www.marketwatch.com/data-news/henry-schein-inc-stock-outperforms-competitors-on-strong-trading-day-e849ef41-13b7b88ae66a?mod=goog_fin_scmw", "external_url": "https://www.marketwatch.com/data-news/henry-schein-inc-stock-outperforms-competitors-on-strong-trading-day-e849ef41-13b7b88ae66a?mod=goog_fin_scmw", "title": "Henry Schein Inc. stock outperforms competitors on strong trading day", "content_text": "Shares of Henry Schein Inc. (HSIC) increased by 1.75% to $90.74 on Wednesday, marking its second consecutive day of gains. This performance occurred during a mixed trading session where the S&P 500 Index rose by 0.26% and the Dow Jones Industrial Average fell by 0.04%.", "date_published": "2026-08-12T19:08:20+00:00", "authors": [{"name": "MarketWatch"}], "tags": ["Earnings", "HSIC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HSIC", "name": "Henry Schein Inc", "sentiment_url": "https://sharemaestro.com/sentiment/7e68109e-ccb7-48b4-baa6-5f2259f53a97/"}]}}, {"id": "source:2fe2f0298979b8539ce3c89c8441b163f5334c839423438f07c7b71103336997", "url": "https://www.marketbeat.com/articles/cardinal-health-earnings-can-perfection-get-priced-in-twice", "external_url": "https://www.marketbeat.com/articles/cardinal-health-earnings-can-perfection-get-priced-in-twice", "title": "Cardinal Health Earnings: Can Perfection Get Priced In Twice?", "content_text": "Cardinal Health (CAH) saw its stock hit a new all-time high despite mixed Q4 fiscal year results, including a revenue miss and a decline in its Global Medical Products and Distribution unit. The company's growth is being driven by its high-margin cell-and-gene-therapy logistics business, which now exclusively serves nearly half of that market, projected to reach $106 billion by 2033. Analysts have raised price targets, and Cardinal Health maintains a 29-year streak of dividend increases, indicating continued investor confidence despite valuation concerns.", "date_published": "2026-08-12T18:37:26+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:ac23b3e1c83f97cb533b110d375f871b6a97a61526ff2c3dceaacef2d2c63547", "url": "https://kalkinemedia.com/us/news/announcements/cencora-reports-walgreens-volume-transition-confirms-fy2026-adjusted-eps-forecast", "external_url": "https://kalkinemedia.com/us/news/announcements/cencora-reports-walgreens-volume-transition-confirms-fy2026-adjusted-eps-forecast", "title": "Cencora Reports Walgreens Volume Transition, Confirms FY2026 Adjusted EPS Forecast", "content_text": "Cencora, Inc. has reported to the SEC that some Walgreens volume began transitioning out of the company on July 1, 2026, a move that was fully anticipated and does not affect their prime vendor agreement with Walgreens. The company reconfirmed its adjusted diluted EPS guidance for fiscal year 2026, setting it between $17.75 and $17.95. This disclosure emphasizes that while a portion of the business is shifting, the core relationship with Walgreens remains strong, and the financial outlook is unchanged.", "date_published": "2026-08-12T17:37:29+00:00", "authors": [{"name": "Kalkine Media"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:fb6c12c6d389ac1347309378940963278b0fd0eb77847eb5ff3103b7563fed80", "url": "https://www.tradingview.com/news/tradingview:312dd8e3cab32:0-cencora-says-certain-walgreens-volume-moves-outside-company-reaffirms-fy26-adjusted-eps-17-75-17-95", "external_url": "https://www.tradingview.com/news/tradingview:312dd8e3cab32:0-cencora-says-certain-walgreens-volume-moves-outside-company-reaffirms-fy26-adjusted-eps-17-75-17-95", "title": "Cencora says certain Walgreens volume moves outside company; reaffirms FY26 adjusted EPS $17.75-$17.95", "content_text": "Cencora announced that certain Walgreens volume began moving outside the company as of July 1, 2026. Despite this change, the prime vendor agreement with Walgreens, which represents the majority of Cencora's Walgreens business, remains unchanged. Cencora reaffirmed its fiscal year 2026 adjusted diluted EPS guidance of $17.75 to $17.95, stating this outcome was anticipated in their August 5, 2026 commentary.", "date_published": "2026-08-12T17:07:34+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:e7c1badc94cb95c24ce07e9ae2d5e151e022851e3bdba3f7b323331ff728f988", "url": "https://seekingalpha.com/news/4631728-cencora-dips-loss-some-walgreens-business", "external_url": "https://seekingalpha.com/news/4631728-cencora-dips-loss-some-walgreens-business", "title": "Cencora dips on loss of some Walgreens business (COR:NYSE)", "content_text": "Cencora's shares experienced a decline in afternoon trading after the medical distributor announced the loss of some business operations previously serving the Walgreens pharmacy chain. The company, formerly known as AmerisourceBergen, stated that certain business activities are moving outside their previous arrangement. This development impacted investor confidence, leading to the stock dip.", "date_published": "2026-08-12T17:07:28+00:00", "authors": [{"name": "Seeking Alpha"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:4c8a1ecb9e67202afc753f0333aed03f4cd327dc250441a9610a6c402cd83a23", "url": "https://za.investing.com/news/stock-market-news/cencora-maintains-earnings-guidance-as-some-walgreens-volume-moves-away-93CH-4425148", "external_url": "https://za.investing.com/news/stock-market-news/cencora-maintains-earnings-guidance-as-some-walgreens-volume-moves-away-93CH-4425148", "title": "Cencora maintains earnings guidance as some Walgreens volume moves away", "content_text": "Cencora (NYSE:COR) announced that some Walgreens volume previously serviced outside of its prime vendor agreement has shifted away, effective July 1. Despite this change, which was anticipated, the company reaffirmed its adjusted diluted earnings per share guidance of $17.75 to $17.95 for fiscal year 2026. Cencora also recently surpassed Wall Street forecasts with strong Q3 2026 results, reporting adjusted earnings of $4.48 per share and revenue of $84.8 billion, leading to a raised profit outlook for the full year.", "date_published": "2026-08-12T16:37:36+00:00", "authors": [{"name": "Investing.com South Africa"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:73377d5f83203082618b8ecd7a67da8925f6ea4f22c50d2dd6b8f5cefc11f91c", "url": "https://finance.yahoo.com/healthcare/articles/cencora-cor-q3-2026-earnings-151445992.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cencora-cor-q3-2026-earnings-151445992.html", "title": "Cencora (COR) Q3 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations and Enterprise Productivity - Bennett Murphy President and Chief Executive Officer - Robert Mauch Executive Vice President and Chief Financial Officer - Eva Boratto Full Conference Call Transcript Operator: Hello, everyone. Thank you for joining us, and welcome to the Cencora Inc. Q3 Fiscal Year 2026 Earnings Call. [Operator Instructions] I will now hand the conference over to Bennett Murphy. Bennett, please go ahead. Bennett Murphy: Good morning, good afterno", "date_published": "2026-08-12T15:14:45+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:b358c0963ae82f51cfb8e27a8dd066eb83bf1f26fed460553f0cb3d05eb0fc23", "url": "https://finance.yahoo.com/healthcare/articles/cah-q4-earnings-call-centers-140000960.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cah-q4-earnings-call-centers-140000960.html", "title": "CAH Q4 Earnings Call Centers on Fiscal 2027 Growth Outlook", "content_text": "Cardinal Health, Inc. CAH used its fourth-quarter fiscal 2026 call to focus on fiscal 2027 profit growth and normalized pharmaceutical demand. Management also emphasized scaling specialty businesses. The company reported fourth-quarter non-GAAP EPS of $2.91, which topped the Zacks Consensus Estimate of $2.42. Revenues of $63.67 billion missed the $65.61 billion estimate. Meanwhile, management spent more time on the outlook. Cardinal Health, Inc. Price, Consensus and EPS SurpriseCardinal Health, Inc. Price, Consensus and EPS Surprise Cardinal Health, Inc. price-consensus-eps-surprise-chart | Ca", "date_published": "2026-08-12T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:4c00746ad5d80dcedfca14f07e55e6b8c0381959de674e8b94ce1dc3a349f242", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9EUFdRUE9rU19ZMWRqbnQ3MUhkQ0xfVmZwaUh5TWZJbkd0NjVyMjM4SEZCTUdJVjZLTDJMM0dVSDJlaGdJNUtqNkw3bkRITUhtYmZB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9EUFdRUE9rU19ZMWRqbnQ3MUhkQ0xfVmZwaUh5TWZJbkd0NjVyMjM4SEZCTUdJVjZLTDJMM0dVSDJlaGdJNUtqNkw3bkRITUhtYmZB?oc=5", "title": "McKesson Corporation (MCK.F) Stock Price, News, Quote & History", "content_text": "McKesson Corporation (MCK.F) Stock Price, News, Quote & History", "date_published": "2026-08-12T13:57:09+00:00", "authors": [{"name": "Yahoo! Finance Canada"}], "tags": ["Market update", "MCK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/f408c6b7-f74b-4900-8d8c-02e6020cfb3f/"}]}}, {"id": "source:e957d90848dd22fdddb202c7af6f4cf53bc7a40b2fa53c802a0d83037878a4c3", "url": "https://www.citybiz.co/article/887803/keurig-dr-pepper-adds-cardinal-health-cfo-aaron-alt-to-board", "external_url": "https://www.citybiz.co/article/887803/keurig-dr-pepper-adds-cardinal-health-cfo-aaron-alt-to-board", "title": "Keurig Dr Pepper Adds Cardinal Health CFO Aaron Alt to Board", "content_text": "Keurig Dr Pepper has appointed Cardinal Health CFO Aaron Alt to its board of directors, effective August 14, 2026. Alt's extensive experience in finance and corporate transformation, including serving as CFO for three public companies, will be crucial as KDP prepares to separate into two independent businesses: Beverage Co. and Global Coffee Co. This appointment aims to strengthen the board's financial capabilities during this significant strategic transition.", "date_published": "2026-08-12T13:02:20+00:00", "authors": [{"name": "citybiz"}], "tags": ["Market update", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:018e7acc5688c6a30d799011b6274f08387349997ce3a77a46c246b039f950ed", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPSGZTQ1Nwc2JzTUtvb3lfMDFscHRubkFFN3hNWUc5c2F3Y19oZHRRQ21vNGVaTUlOVmNiejlUTnBka19iMHFfamxacFg1QlVpT19WM3V3aHNFVmRWaDBTV1VwWlpOS0ZXQW1GekFxRXlZUW5MSUFfWVF2WTZIRUV3MmoycFhCVzJBRjFDNWd2TUVkeHZMYXZ2WUprR014RGJBTkFfekxOTm1FMkdPMEFla3ZYeHZ0MHYxWlVHVkpicWxORGRoejc3b3BIWGE4SWtrN1lGWVJGRXRWNzg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPSGZTQ1Nwc2JzTUtvb3lfMDFscHRubkFFN3hNWUc5c2F3Y19oZHRRQ21vNGVaTUlOVmNiejlUTnBka19iMHFfamxacFg1QlVpT19WM3V3aHNFVmRWaDBTV1VwWlpOS0ZXQW1GekFxRXlZUW5MSUFfWVF2WTZIRUV3MmoycFhCVzJBRjFDNWd2TUVkeHZMYXZ2WUprR014RGJBTkFfekxOTm1FMkdPMEFla3ZYeHZ0MHYxWlVHVkpicWxORGRoejc3b3BIWGE4SWtrN1lGWVJGRXRWNzg?oc=5", "title": "Wells Fargo & Company Forecasts Strong Price Appreciation for Cardinal Health (NYSE:CAH) Stock", "content_text": "Wells Fargo & Company Forecasts Strong Price Appreciation for Cardinal Health (NYSE:CAH) Stock", "date_published": "2026-08-12T12:36:32+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:0fe8977c90c86d3b9a77351d472e4e4024fee9a7a0eb67a328ce35cffb29e1ff", "url": "https://finance.yahoo.com/markets/stocks/articles/keurig-dr-pepper-announces-appointment-120000961.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/keurig-dr-pepper-announces-appointment-120000961.html", "title": "Keurig Dr Pepper Announces Appointment of New Director to its Board", "content_text": "FRISCO, Texas and BURLINGTON, Mass., Aug. 12, 2026 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ: KDP) announced today that Aaron Alt has been appointed a director of the Company's Board of Directors, effective August 14, 2026. Alt brings deep expertise in finance, capital allocation and business transformation to KDP's Board and will serve on its Audit and Finance Committee. He currently serves as Chief Financial Officer of Cardinal Health, where he oversees the company's financial and corporate development activities. Prior to joining Cardinal Health in 2023, Alt served as Executive Vice Pre", "date_published": "2026-08-12T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:b4e745b7566d650eb9a6dc064184ae5acd328816f8ec79fe2b39f0bc322eda25", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOVG1oYUFKXzN1TXN3d2FDal9Ub3lZcVNaekttX2wzZjlkVTIxc3FzVlFxUGlERDdGMWI2d1NWNmdBdkxyN1V2Um5VVmtvMXZkbWRoakdha2F1cFh2bkhzTmNUWFRUbFgyNmMySEI4cjVLSjkzY0c3LTdMdzhtNHJkN0NyYkFRTTlMRExlcHg0dUxfc0hXMHFoZTAtNkdBdFhxeWdaNDFzazAxTHNOOFVyVndSSWIweEUtNWFXeDk2c3RkQTF6NGc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOVG1oYUFKXzN1TXN3d2FDal9Ub3lZcVNaekttX2wzZjlkVTIxc3FzVlFxUGlERDdGMWI2d1NWNmdBdkxyN1V2Um5VVmtvMXZkbWRoakdha2F1cFh2bkhzTmNUWFRUbFgyNmMySEI4cjVLSjkzY0c3LTdMdzhtNHJkN0NyYkFRTTlMRExlcHg0dUxfc0hXMHFoZTAtNkdBdFhxeWdaNDFzazAxTHNOOFVyVndSSWIweEUtNWFXeDk2c3RkQTF6NGc?oc=5", "title": "Mizuho raises Cardinal Health stock price target to $250 on earnings", "content_text": "Mizuho raises Cardinal Health stock price target to $250 on earnings", "date_published": "2026-08-12T11:59:48+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:cc276e1eb5701ad54425d5ea1ae8d3631eff6628068a527e320e52be50417c9d", "url": "https://finance.yahoo.com/markets/stocks/articles/company-news-aug-12-2026-112200806.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/company-news-aug-12-2026-112200806.html", "title": "Company News for Aug 12, 2026", "content_text": "Fermi Inc. (FRMI) shares climbed 21.1% after signing a $6.5 billion lease agreement with AI cloud provider TensorWave. Aramark (ARMK) shares rose 8.5% after the company reported third-quarter 2026 earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.48 per share. Plug Power Inc. (PLUG) shares rose 5.2% after the company reported second-quarter 2026 revenues of $178.3 million, surpassing the Zacks Consensus Estimate by 6.30%. Cardinal Health, Inc. (CAH) shares rose 1.3% after the company reported fourth-quarter 2026 earnings of $2.91 per share, beating the Zacks Consensus Est", "date_published": "2026-08-12T11:22:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:4f379605c33bd35fdd5115875dbc3e2132fb33d170835160fcfb8db84b8af8fd", "url": "https://www.marketbeat.com/instant-alerts/filing-wedge-capital-management-l-l-p-nc-increases-position-in-cencora-inc-cor-2026-08-12", "external_url": "https://www.marketbeat.com/instant-alerts/filing-wedge-capital-management-l-l-p-nc-increases-position-in-cencora-inc-cor-2026-08-12", "title": "Wedge Capital Management L L P NC Increases Position in Cencora, Inc. $COR", "content_text": "Wedge Capital Management L L P NC has increased its stake in Cencora, Inc. (NYSE:COR) by 31.0% during the second quarter, bringing its total holdings to 105,614 shares valued at approximately $29.9 million. Institutional investors and hedge funds collectively own 97.52% of the company's stock. Cencora has reported strong financials, beating earnings expectations with $4.48 adjusted EPS on $84.75 billion in revenue, and analysts maintain a \"Moderate Buy\" rating with an average price target of $374.25.", "date_published": "2026-08-12T11:20:03+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:e225d6878c1ff5503048acddae2ca7269b01cfdcce59dcca426632d263daeade", "url": "https://www.marketbeat.com/instant-alerts/filing-wedge-capital-management-l-l-p-nc-has-2942-million-position-in-mckesson-corporation-mck-2026-08-12", "external_url": "https://www.marketbeat.com/instant-alerts/filing-wedge-capital-management-l-l-p-nc-has-2942-million-position-in-mckesson-corporation-mck-2026-08-12", "title": "Wedge Capital Management L L P NC Has $29.42 Million Position in McKesson Corporation $MCK", "content_text": "Wedge Capital Management L L P NC significantly increased its stake in McKesson Corporation (NYSE:MCK) by 22.5% in the second quarter, bringing its total holdings to 38,937 shares valued at $29.42 million. This move is part of a broader trend of institutional investment, with McKesson reporting strong financial results including an EPS of $9.93 and a 7.7% year-over-year revenue increase to $105.38 billion, alongside a dividend increase. Despite some insider selling, analysts maintain a \"Moderate Buy\" rating with an average price target of $977.00 for MCK.", "date_published": "2026-08-12T11:14:06+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "MCK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/f408c6b7-f74b-4900-8d8c-02e6020cfb3f/"}]}}, {"id": "source:da1d8289ac16f46585a8ab47b86b3aa688df8016153872e3c3e3b0df90ffea6e", "url": "https://www.marketbeat.com/instant-alerts/filing-insight-wealth-strategies-llc-purchases-6648-shares-of-cencora-inc-cor-2026-08-12", "external_url": "https://www.marketbeat.com/instant-alerts/filing-insight-wealth-strategies-llc-purchases-6648-shares-of-cencora-inc-cor-2026-08-12", "title": "Insight Wealth Strategies LLC Purchases 6,648 Shares of Cencora, Inc. $COR", "content_text": "Insight Wealth Strategies LLC increased its stake in Cencora, Inc. by 37.6% in the second quarter, adding 6,648 shares. Institutional investors hold 97.52% of the company, and analysts have a \"Moderate Buy\" consensus with an average price target of $374.25. Cencora also surpassed earnings and revenue expectations, reported a quarterly dividend of $0.60 per share, and authorized a $2 billion share-buyback program.", "date_published": "2026-08-12T11:00:04+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:2a6462e162c5897d8b46a7dfe0f511e5dcfc838a4850f7177d8a4fc336c08410", "url": "https://www.tradingview.com/news/tradingview:b9285f3ae788b:0-snyr-q2-26-earnings-eps-estimate-is-0-01-usd", "external_url": "https://www.tradingview.com/news/tradingview:b9285f3ae788b:0-snyr-q2-26-earnings-eps-estimate-is-0-01-usd", "title": "SNYR Q2'26 Earnings: EPS estimate is (0.01) USD", "content_text": "Synergy CHC Corp. (SNYR) is scheduled to release its Q2'26 earnings on August 13, with an estimated revenue of $8.00 million and an EPS of ($0.01). The report will provide insight into the company's financial performance compared to previous quarters and analyst expectations.", "date_published": "2026-08-12T10:40:09+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "SNYR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SNYR", "name": "Synergy CHC Corp. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/e6019e1a-7683-4b77-92d8-a1d8182df2f9/"}]}}, {"id": "source:b95d474d5a540de03d49bf7de79d44a07f2b25eb356852c6d3da3b5e7e86b15f", "url": "https://www.marketbeat.com/instant-alerts/filing-handelsbanken-fonder-ab-acquires-14919-shares-of-cardinal-health-inc-cah-2026-08-12", "external_url": "https://www.marketbeat.com/instant-alerts/filing-handelsbanken-fonder-ab-acquires-14919-shares-of-cardinal-health-inc-cah-2026-08-12", "title": "Handelsbanken Fonder AB Acquires 14,919 Shares of Cardinal Health, Inc. $CAH", "content_text": "Handelsbanken Fonder AB increased its stake in Cardinal Health, Inc. (NYSE:CAH) by 12.5% in the second quarter, acquiring an additional 14,919 shares. This move is part of broader institutional investor activity in Cardinal Health, which has recently seen positive news including an earnings beat, strong fiscal 2027 guidance, a large share buyback authorization, and growth in cell and gene therapy logistics. The company also announced a quarterly dividend, while analysts maintain a \"Moderate Buy\" consensus rating.", "date_published": "2026-08-12T09:47:49+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:24b96e6250e135354f4536c20765ea21c9779593d2c503f5b2aa303d56b5c951", "url": "https://www.sahmcapital.com/news/content/henry-scheins-nasdaqhsic-earnings-seem-to-be-promising-2026-08-12", "external_url": "https://www.sahmcapital.com/news/content/henry-scheins-nasdaqhsic-earnings-seem-to-be-promising-2026-08-12", "title": "Henry Schein's (NASDAQ:HSIC) Earnings Seem To Be Promising", "content_text": "Henry Schein's recent earnings report was unchanged, but underlying numbers suggest encouraging factors for investors. The company incurred a significant US$103m expense due to unusual items, which, if not repeated, could lead to higher profits next year. Analysts predict improved profitability, and the company's earnings per share increased by 10% last year, indicating strong earnings potential.", "date_published": "2026-08-12T09:38:13+00:00", "authors": [{"name": "Sahm"}], "tags": ["Earnings", "HSIC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HSIC", "name": "Henry Schein Inc", "sentiment_url": "https://sharemaestro.com/sentiment/7e68109e-ccb7-48b4-baa6-5f2259f53a97/"}]}}, {"id": "source:6dd55ebacb83ae1246ed5247a2085bca3c7b244609151612cd847cb867803bdf", "url": "https://www.tikr.com/blog/cardinal-healths-q4-earnings-explained-a-revenue-miss-a-profit-beat", "external_url": "https://www.tikr.com/blog/cardinal-healths-q4-earnings-explained-a-revenue-miss-a-profit-beat", "title": "Cardinal Health\u2019s Q4 Earnings Explained: A Revenue Miss, a Profit Beat", "content_text": "Cardinal Health's Q4 earnings for fiscal 2026 showed a revenue miss but a significant profit beat, largely due to a one-time $100 million IEEPA tariff refund. Despite the non-recurring benefit, the company raised its fiscal 2027 adjusted EPS guidance, indicating strong underlying growth driven by its Pharma segment and specialty products. TIKR's model values Cardinal Health stock at $328 by mid-2032, suggesting a 7% annualized return.", "date_published": "2026-08-12T09:37:35+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}, {"id": "source:096ef3f68e5e19e9eb8c5724425c14161ceda3aff691e1af925e266b44f58c80", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/3784579/henry-schein-hsic-q2-2026-earnings-call-transcript", "external_url": "https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/3784579/henry-schein-hsic-q2-2026-earnings-call-transcript", "title": "Henry Schein (HSIC) Q2 2026 Earnings Call Transcript", "content_text": "Henry Schein (HSIC) reported strong Q2 2026 results with total net sales of $3.5 billion, a 6.7% increase, and non-GAAP diluted EPS of $1.27, up 15.5%. The company raised its full-year 2026 sales and non-GAAP EPS guidance, driven by accelerated internal local currency growth, expanded operating margins, and the initial benefits of value creation initiatives. Management highlighted the strong performance of its cloud-based technology solutions, own brands, and growth in the DSO segment, while also discussing plans for operational rigor and disciplined capital deployment.", "date_published": "2026-08-12T09:08:18+00:00", "authors": [{"name": "The Globe and Mail"}], "tags": ["Earnings", "HSIC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HSIC", "name": "Henry Schein Inc", "sentiment_url": "https://sharemaestro.com/sentiment/7e68109e-ccb7-48b4-baa6-5f2259f53a97/"}]}}, {"id": "source:725cdc2008db873d64e658c758bcf4ed9e80627c38054193be9f41278642f761", "url": "https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-almr-30-q2-reports-dyn-cgem-dxcm-cah", "external_url": "https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-almr-30-q2-reports-dyn-cgem-dxcm-cah", "title": "Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH", "content_text": "(RTTNews) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports. Alamar Biosciences Inc. (ALMR) Alamar Biosciences is a proteomics company that has develops a liquid biopsy platform alongside instruments and services for the early detection of diseases. Following a rise of over 30%, the company hit a 52-week high of $38.54 on Tuesday. On Monday, the company stated that net losses in the second quarter widened to $13.19 million, compared to $7.02 million in the previous year. Total revenue surged to $", "date_published": "2026-08-12T07:45:56+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/038bee6c-d302-406e-842f-ff583380e49c/"}]}}]}